This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo® is a fifth-generation cephalosporin with coverage against key pathogens in cSSTI and CAP1,2

Increased range of activity relative to third-generation compounds2

Rapid bactericidal in vitro activity against resistant Gram-positive pathogens, including MRSA in cSSTI and penicillin-resistant Streptococcus pneumoniae in CAPˠ1–4

Clinical efficacy has been demonstrated against the following pathogens:†1

Gram-negative

Gram-positive

Klebsiella pneumoniae

Staphylococcus aureus (MSSA only)

Haemophilius influenzae

Streptococcus pneumoniaeˠ

Haemophilius parainfluenzae

Escherichia coli

Gram-negative

Gram-positive

Escherichia coli

Staphylococcus aureus (MRSA & MSSA)

Klebsiella pneumoniae

Streptococcus pyogenes

Klebsiella oxytoca

Streptococcus agalactiae

Morganella morganii

Streptococcus anginosus group

Streptococcus dysgalactiae

Staphylococcus aureus and Streptococcus pneumoniae are key pathogens in cSSTI and CAP in paediatric patientsˠ5-8,11,12,14-16

S.aureus, including methicillin-resistant strains, is a major cause of cSSTI in children and adults5,6

S. pneumoniae is the most common pathogen associated with CAP in childhood.ˠ7-10 S.aureus has also emerged as a key causative pathogen.7-9

Infections caused by these pathogens are associated with increased rates of hospitalisation, complications (e.g. empyema) and mortality5,6,8,11-13

Explore more

Investigate the outcomes of the Zinforo Phase III clinical trials in adult patients with CAP and cSSTI ​​​​​​​

Efficacy
†Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
ˠThe available clinical data cannot substantiate efficacy against penicillin non-susceptible strains of S.pneumoniae.1
‡There is no experience with Zinforo in the treatment of CAP in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease, those with PORT Risk Class V, and/or CAP requiring ventilation at presentation, CAP due to methicillin-resistant S. aureus or patients requiring intensive care. Caution is advised when treating such patients.1



Abbreviations
​​​​​​​
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References
  1. ZINFORO. Summary of Product Characteristics
  2. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  3. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  4. Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7
  5. Korczowski B, et al. Pediatr Infect Dis J 2016;35:e239–47
  6. Suaya JA, et al. BMC infect Dis 2014;14:296
  7. Cannavino CR, et al. Pediatr Infect Dis J 2016;35:752–59
  8. Dona D, et al. Int J Pediatr 2017; article ID 4239268
  9. Rodrigues CMC. Curr Ther Res Clin Exp 2017;84:e7–11
  10. García-Elorriaga G and Del Rey-Pineda G. J Pediatr Infect Dis 2016;1(1:3)
  11. Harris M, et al. Thorax 2011;66:ii1–23
  12. Williams DJ, et al. Pediatrics 2011;128:e479–87
  13. Moore SJ, et al. Pediatr Infect Dis J 2014;33:825–8
  14. le Roux DM and Zar HJ. Pediatr Radiol 2017;47:1392–8
    15. Schuler CL, et al. Pediatrics 2018;137:e20181420
    16. Ray GT, et al. BMC Infect Dis 2013;13:252
PP-ZFO-GBR-0220. September 2021

Discover specific information on the use of Zinforo in neonates, infants and children here:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No